Key result
The MACH-1 trial was designed to evaluate whether mibefradil reduces mortality and improves symptoms in 2,400 patients with heart failure, with no results reported in this design abstract.
Why the study?
Does mibefradil reduce mortality in patients with symptomatic heart failure on standard therapy?
RCT (n=2,400)
Double-blind
Yes
Does mibefradil reduce mortality in patients with symptomatic heart failure on standard therapy?
This paper describes the design of the MACH-1 trial, which aims to evaluate whether mibefradil reduces mortality in patients with symptomatic heart failure.
Answers are grounded in this paper and cite their sources.
Launches RCT testing mibefradil addition in symptomatic HF; will determine if T-channel blockade reduces mortality on standard therapy.
BACKGROUND: Despite the advances in therapy for heart failure with the use of angiotensin-converting enzyme inhibitors, heart failure remains a major medical problem, impacting on well-being and survival. HYPOTHESIS: Mibefradil is a member of new class of agents that, due to its unique mechanism of action and pharmacologic and physiologic profile, may offer a significant advance in the treatment of heart failure. Mibefradil is a nonvoltage-regulated T-channel calcium blocker that differs from all the other currently available L-channel calcium blockers. The drug is a potent peripheral and coronary vasodilator, with no clinical negative inotropic activity. Furthermore, because of its long half-life, it can be given once a day and appears to be free of the common side effects seen with other calcium-channel blockers. The trial was designed to investigate whether the addition of mibefradil to standard therapy for heart failure will reduce mortality in patients with symptomatic heart failure. METHODS: This manuscript describes the design, organization, and status of MACH-1 (Mortality Assessment in Congestive Heart Failure), a double-blind, placebo-controlled study. It is to be a 2,400-patient international trial assessing the ability of mibefradil to impact upon survival and symptoms of heart failure in patients who are in NYHA classes II-IV and who were already treated with standard therapy.
No takes yet. Share an insight, caveat, or question.
T. Barry Levine (1997) conducted an RCT in Congestive heart failure (n=2,400). Mibefradil vs. Placebo was evaluated on Mortality (survival) and symptoms of heart failure. The MACH-1 trial was designed to evaluate whether mibefradil reduces mortality and improves symptoms in 2,400 patients with heart failure, with no results reported in this design abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: